**Core Concept:**
Hyperkalemia is a condition characterized by an increase in potassium levels in the blood, which can lead to detrimental effects on cardiac and skeletal muscles. The peaked T waves observed on an electrocardiogram (ECG) can indicate myocardial damage or dysfunction, as potassium levels rise. Treatment aims to reduce potassium levels and restore normal ECG findings.

**Why the Correct Answer is Right:**
The fastest way to shift potassium intracellularly is through the use of the sodium-potassium pump (Na+/K+-ATPase). This pump actively transports one potassium ion (K+) out of the cell and three sodium ions (Na+) into the cell, maintaining the balance of ions and thus helping to normalize potassium levels.

**Why Each Wrong Option is Incorrect:**
A. Glibenclamide (a sulfonylurea) is a hypoglycemic agent used to treat diabetes mellitus, not for treating hyperkalemia. It does not directly help in shifting potassium ions intracellularly.
B. Insulin is a hormone primarily involved in regulating blood glucose levels and not for correcting hyperkalemia. It does not facilitate the active transport of potassium ions.
C. Calcium channel blockers (e.g., verapamil) are used to treat hypertension and arrhythmias, not for hyperkalemia management. They do not directly help in shifting potassium ions intracellularly.
D. Spironolactone is a diuretic that promotes potassium excretion in the kidneys, but it does not directly address the intracellular shift of potassium ions.

**Clinical Pearl:**
In clinical practice, the treatment of choice for hyperkalemia is typically insulin with glucose (or calcium gluconate) therapy, as it can potentially lower extracellular potassium levels. However, the option discussed here, Na+/K+-ATPase, is the fastest way to shift potassium ions intracellularly to counteract hyperkalemia, but it is not a direct treatment modality.